Evidence map›Paper›PMID 39605848›Full record

ArticleClinical case reports2024

Possible Factor Xa Resistance in a Patient Who Failed Apixaban and Rivaroxaban.

Ola Ali, Awab Elnaeem, Manmeet Kaur, Nitisha Thatikonda, Julia Aigbogun, A K M Muktadir

Abstract read
In one paragraph

Article in Clinical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ola AliCollege of Medicine University of Bahri Khartoum Sudan.ORCID https://orcid.org/0009-0005-5310-1950
Awab ElnaeemDepartment of Neurology University of Texas Medical Branch Galveston Texas USA.
Manmeet KaurDepartment of Neurology University of Texas Medical Branch Galveston Texas USA.
Nitisha ThatikondaDepartment of Neurology University of Texas Medical Branch Galveston Texas USA.
Julia AigbogunDepartment of Neurology University of Texas Medical Branch Galveston Texas USA.
A K M MuktadirDepartment of Neurology University of Texas Medical Branch Galveston Texas USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article aims to discuss the literature on switching to an anticoagulant with a different mechanism of action in case of treatment failure. We present a patient with atrial fibrillation who incurred an embolic stroke despite adequate anticoagulation with apixaban and developed a new symptomatic ischemic stroke during the same admission after switching to rivaroxaban, a factor Xa inhibitor with a similar mechanism of action. He had no new events at 3-months after switching to dabigatran, a direct thrombin inhibitor. We identified no apparent reason for anticoagulation failure in our patient. The literature on switching anticoagulants in case of failure is inconclusive with no strong supportive evidence. More research is needed to define anticoagulation failure and identify cases with factor Xa inhibitor resistance, in which switching to a different mechanism of anticoagulation may be appropriate.

Indexed as

atrial fibrillationdirect oral anticoagulantsnovel oral anticoagulantsswitching anticoagulantstreatment failure

Identifiers

PMID39605848
PMCPMC11599160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.